Modus Therapeutics Holding AB (99Z) Stock Price & Analysis

99Z Stock Chart & Stats

€0.01-€0.01(-50.00%)

At close: Oct 16 2:00 AM GMT+2

Day’s Range: EUR 0.01 - EUR 0.01
52-Week Range: EUR 0.01 - EUR 0.04
Previous Close: EUR 0.02
Volume: N/A
Average Volume (3M): 0
Market Cap: EUR 2.85M
Enterprise Value: EUR 39.62M
Total Cash (Recent Filing): EUR 12.49M
Total Debt (Recent Filing): EUR 0
Price to Earnings (P/E): ―
Beta: 2.30
Next Earnings: Nov 24, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

The absence of debt reduces interest obligations and near-term refinancing pressure, giving Modus greater financial flexibility while it advances development programs. This conservative capital structure can help preserve strategic options during clinical execution and future financing decisions.

Improved Equity Base

A materially stronger equity base provides a larger capital cushion than in prior periods and supports continued operations as the company develops its pipeline. Although it does not eliminate funding needs, improved capitalization may increase resilience and support access to future financing.

Focused Disease Pipeline

A focused development strategy in sickle cell disease and related hematologic conditions gives Modus a clear therapeutic identity and concentrates research resources on a defined medical need. Progress in this area could create meaningful long-term value if candidates demonstrate clinical benefit.

Bears Say

Pre-Revenue Business Model

The absence of product revenue means Modus has not yet established a commercial income stream to fund operations or validate recurring demand. Its financial outlook therefore remains dependent on successful development, approval, partnering, or other future monetization milestones.

Persistent Operating Losses

Large and continuing operating and net losses show that the company has not achieved profitability or operating leverage. Without a sustained narrowing of losses, future growth will continue to consume capital and the path to self-funded operations will remain uncertain.

High Cash Burn

Materially negative operating and free cash flow indicates that Modus is consuming cash to maintain its development activities rather than generating funds internally. Persistent burn creates ongoing dependence on external capital and can constrain the pace and scope of future programs.

99Z FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was €0.01 and its highest was €0.04 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is €2.85M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on Aug 26, 2026. The company reported -€0.003 earnings per share for the quarter.

Is Modus Therapeutics Holding AB overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 169,036,960 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -€0.003 in its last earnings report. Following the earnings report the stock price went down -4.545%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in DE:99Z

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description